NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, expanded on the information provided Monday at the H.C. Wainwright BioConnect Virtual Conference regarding the BriLife™ investigational vaccine for COVID-19.
Yesterday, the Israel Institute for Biological Research (IIBR) announced that it is currently studying the new Omicron variant of the SARS-CoV-2 to assess the extent to which this variant is neutralized by antibodies produced by the BriLife™ COVID-19 vaccine.
Analysis of Blood Samples from Patients who Responded to the BriLife® Vaccine During Phase 2 Trial Suggests that the Same Level of Response was Seen Against the Delta Variant as Against the Original “Wild-Type” Virus Data Suggest that the BriLife Vaccine May Be Capable of Evolving to Counter Delta and Other Variants of Concern NRx […]
NRx Enters into Negotiations for Financing and Manufacturing Capacity with BNP Paribas to serve European and Adjacent Markets Tech Transfer and Scaleup of BriLife™ COVID-19 Vaccine to Commence in November 2021 Targeting Initiation of GMP Vaccine Manufacture in First Half of 2022 RADNOR, Pa., Nov. 5, 2021 /PRNewswire/ — NRx Pharmaceuticals (NASDAQ: NRXP), via its subsidiary, NRx Luxembourg (NRx), […]
NRx Pharmaceuticals to lead BriLife Vaccine Trial in Caucasus Region NRx Pharmaceuticals with Support from the Israel Institute for Biological Research to lead BriLife Vaccine Development and Commercialization RADNOR, Pa., Aug. 23, 2021 /PRNewswire/ — NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, biopharmaceutical company noted today reports1 in the Israeli media that participants in the BriLife vaccine trial who […]
NRx Pharmaceuticals Announces Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife™ COVID Vaccine
Cheddar News – Apr 15, 2021 12:02 am
